New Study Confirms Quatrefolic® as an Effective Solution to Support a Healthy Pregnancy during the Second Trimester
Adequate folate intake is essential during pregnancy, particularly for maternal health and fetal development. While folic acid has long been the standard form used in prenatal supplementation, 5-methyltetrahydrofolate (5-MTHF) offers an alternative: it is the predominant circulating form of folate in the human body and does not require the same metabolic conversion steps as folic acid to become biologically active.
A new randomized controlled trial, published in Clinical Nutrition ESPEN in 2026, provides further insights into the comparative effects of these two forms of folate in pregnant women.
The double-blind randomized controlled trial enrolled 110 pregnant women at 9–14 weeks of gestation. A total of 96 women completed the study.
The key findings were:
Quatrefolic® is already in the biologically active form used in key folate-dependent metabolic processes. Bypassing the conversion steps required by folic acid provides a direct source of active folate.
For supplement manufacturers developing prenatal products, Quatrefolic® offers the opportunity to draw on scientific evidence regarding active folate, which confirms its efficacy and safety in supporting the health of pregnant women and the development of the unborn child.